ClinicalTrials.gg
TerminatedNCT00332826Updated May 4, 2012

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

A Phase 3 interventional study of Technosphere Insulin in Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 and Asthma, sponsored by Mannkind Corporation. Terminated at 78 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-04.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Why this study was terminated
Non-safety related business decision to combine special population protocols

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
35th of 35
3 · median 74
Started
2006
with 3 others
Phase 3
17 of 35
none open now
Registered
4th of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 35th largest by enrollment, is one of 4 that started in 2006, is one of 17 in phase 3, and was the 4th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The clinical trial is designed to evaluate the safety of inhaled Technosphere/Insulin compared with non-inhaled anti-diabetic therapies in subjects with type 1 or type 2 diabetes mellitus and concurrent asthma.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Asthma

Keywords

  • Inhaled insulin
  • Diabetes Type I and II with Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of Step 1 to 3 asthma as per the NAEPP guidelines
  • Clinical diagnosis of Type 1 or Type 2 diabetes mellitus for at least 1 year
  • Current stable anti-diabetic regimen (insulin alone or in combination with oral anti-hyperglycemic agents)
  • Subjects must exhibit \<30% variability in PEF measurements during the 2 week run in period.
  • Subjects must not meet any criteria for exacerbations of asthma during the 2 week run in period
  • (BMI) \< 40kg/m2
  • >6.0% to \<11.5%

Exclusion criteria

Exclusion Criteria:

  • Severe complications of diabetes in the opinion of the investigator
  • Seizure disorder
  • Significant cardiovascular dysfunction and/or history within 3 months of screening
  • Hypertension with systolic blood pressure of !80 mm Hg and/or diastolic blood pressure >110 mm HG at screening despite pharmacologic therapy.
  • Clinical nephrotic syndrome or renal dysfunction or disease
  • Total daily insulin requirement of >1.4 U/kg body weight
  • Clinical diagnosis of Step 4 asthma
  • Use of >6 puffs/day of fast acting bronchodilator
  • Currently using an insulin delivery pump
  • Use of Pramlintide acetate or any incretins must be discontinued 8 weeks prior to screening
  • Two or more severe hypoglycemic episodes within the past 6 months.
  • Any hospitalization or emergency room visit due to poor diabetic control with 6 months of screening.
  • Current use of systemic
  • Subjects who currently smoke tobacco or who have smoked within the past 6 months
  • Urine cotinine test of > 100ng/ml
  • Current drug or alcohol abuse
  • abnormalities on screening laboratory evaluation
  • Cancer within the past 5 years or any history of lung neoplasms
  • History of active and/or cirrhotic hepatic disease and/or abnormal liver enzymes.
  • Active infection or history of severe infection with 30 days of screening.
  • Anemia
  • History of anaphylaxis and/or angioneurotic edema
  • Diagnosis of (COPE)
  • Previous exposure to any inhaled insulin product
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary safety outcome will be measurements of post bronchodilator FEV1 throughout the treatment period

07

Study locations

78 sites
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Northwest Medical Center
    Phoenix, Arizona 85029, United States
  • Premiere Pharmaceutical Research LLC
    Tempe, Arizona 85282, United States
  • Canyon Internal Medicine
    Tucson, Arizona 85712, United States
  • Associated Pharmaceutical Research Center Inc
    Buena Park, California 90620, United States
  • Family Medical Center
    Foothill Ranch, California 92610, United States
  • Health Care Partners Medical Group
    Long Beach, California 90806, United States
  • Golden Pine Clinical Research
    Long Beach, California 90807, United States
  • Keck USC School of Medicine
    Los Angeles, California 90033, United States
  • Pinaccle Trials Inc (SMO)
    Atlanta, Georgia 30329, United States
  • Executive Health and Research Associates Inc
    Atlanta, Georgia 30342, United States
  • Atlanta Pharmaceutical Research Center
    Dunwoody, Georgia 30338, United States
  • Southeastern Endocrine & Diabetes
    Roswell, Georgia 30076, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Franklin Square Hospital
    Baltimore, Maryland 21237, United States
  • Healthcare Research
    Florissant, Missouri 63031, United States
  • MedEx Healthcare Research Inc(009)
    St Louis, Missouri 63117, United States
  • Billings Clinic Research Division
    Billings, Montana 59101, United States
  • Your Doctors Care
    Hillsborough, New Jersey 08844, United States
  • Hopewell Valley Family Medicine PA
    Trenton, New Jersey 08618, United States
  • Eastside Comprehensive Medical Center
    New York, New York 10021, United States
  • Carolinas Research
    Concord, North Carolina 28025, United States
  • Cleveland Clinic Dept of Endocrinology
    Cleveland, Ohio 44195, United States
  • Diabetes & Glandular Disease Research Assoc PA
    San Antonio, Texas 78229, United States
  • McLennan County Medical Education and Research Foundation
    Waco, Texas 76707, United States
  • DIM (Clinica Privada)
    Buenos Aires, 1704, Argentina
  • Ins De Inv Cardiovascular La Plata
    La Plata, Argentina
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, 90035-070, Brazil
  • Hospital Sao Lucas - PUCRS (Fritscher)
    Porto Alegre, 90610-000, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, 91350-200, Brazil
  • Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda
    Rio de Janeiro, 22271-100, Brazil
  • CPClin-Centro de Pesquisas Clinicas
    Sao Paulo, 01244-030, Brazil
  • Clinica de Endocrinologia
    Sao Paulo, 01323-001, Brazil
  • Finchlea Medical Group
    Brampton, Ontario L6T 3J1, Canada
  • Courtice Health Centre
    Courtice, Ontario L1E 3C3, Canada
  • Parkwood Hospital
    London, Ontario N6C 5J1, Canada
  • The London Road Diagnostic Clinic and Medical Centre
    Sarnia, Ontario N7T 4X3, Canada
  • Albany Medical Center
    Toronto, Ontario M4K 1N5, Canada
  • Windsor Professional Research
    Windsor, Ontario N8X 3V6, Canada
  • Surgery of Diabetology
    Melnik, CZE 276 01, Czech Republic
  • Interni oddeleni nemocnice Na Homolce
    Praha 5, CZE 15031, Czech Republic
  • Diabetologicka Outpatient Surgery of Diabetology
    Slany, CZE 274 01, Czech Republic
  • InternÃ- a diabetologická Outpatient
    Ostrava, 70900, Czech Republic
  • I InternÃ- klinika
    Ostrava, 728 80, Czech Republic
  • Hospital Angeles Mocel
    Mexico City, DF 06726, Mexico
  • Mexican Institute of Clinical Research
    Mexico City, MX 06700, Mexico
  • Nuevo Sanatorio Durango
    Delegacion Cuauhtemoc, 6700, Mexico
  • Hospital Angeles de las Lomas
    Huixquilucan, 52760, Mexico
  • Klinika Endocrinologii Diabetologii I
    Bialystock, POL 15-276, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno - Diabetologiczny
    Bialystok, POL 15-435, Poland
  • Dzial Badan Klinicznych Malopoiskie
    Krakow, POL 30 510, Poland
  • III Oddzial Chorob Wewnetrznych Szpital
    Krakow, POL 31121, Poland
  • Oddzial Chorob Wewnetrznych Wojewodzki
    Lodz, Zgierz 95-100, Poland
  • Oddzial Kliniczny Diabetologii (009) Kliniczny nr 1 im Norberta Barlickiego Uniwersytety Meycznego
    Lodz, 90-153, Poland
  • NHI Kemerovo Regional Clinical Hospital
    Kemerovo, RUS 650061, Russian Federation
  • NI Principal Military Clinical Hospital n a academician N.N. Burdenko
    Moscow, RUS 105229, Russian Federation
  • Moscow State Medico-Stomatological University City Hospital # 23
    Moscow, RUS 109240, Russian Federation
  • Smolensk Medical Academy Smolensk Regional Clinical Hospital
    Smolensk, RUS 214018, Russian Federation
  • Central Medical Sanitary Unit #122
    St Petersburg, RUS 194291, Russian Federation
  • City Hospital # 2 Endocrinology Department
    St. Petersburg, RUS 194354, Russian Federation
  • Yaroslavl Municipal Health Care Institution Clinical Hospital for Emergency Care na NV Soloviev
    Yaroslavl, RUS 150003, Russian Federation
  • Federal State Institution Pulmonology Research Institute of Federal Agency of HC&SD
    Moscow, 105077, Russian Federation
  • City Clinical Hospital #64 Center of Applied Clinical Paharmacology Friendship University
    Moscow, 117 198, Russian Federation
  • Central Clinical Hospital of Russian Science Academy
    Moscow, 117 593, Russian Federation
  • City Clinical Hospital # 61
    Moscow, 119 048, Russian Federation
  • Russian Scientific Center of Restoration Medicine & Balneology
    Moscow, 121069, Russian Federation
  • St Petersburg Medical Academy (Ilkovich)
    St Petersburg, Russian Federation
  • Hospital 2 de Maig
    Barcelona, 30108025, Spain
  • Donetsk State Medical University
    Donetsk, UKR 83003, Ukraine
  • Donetsk State Medical University
    Donetsk, UKR 83009, Ukraine
  • Railway Clinical Hospital on Donetsk Station
    Donetsk, UKR 83114, Ukraine
  • Chair Family Med of National Med University
    Kiev, UKR 04050, Ukraine
  • Institute of Endocrinology and Metabolism
    Kiev, UKR 04114, Ukraine
  • Clinical Research Centre The Royal London Hospital
    London, GBR E1 2AT, United Kingdom
  • Northern General Hospital
    Sheffield, GBR S5 7AU, United Kingdom
  • Birmingham Heartland Hospital
    West Midlands, GBR B9 5SS, United Kingdom
  • Addenbrooke's Hospital Department of Medicine
    Cambridge, CB2 2QQ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2006
First posted
Jun 2, 2006
Start
Jun 2006
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Last update
May 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00332826
First posted
Jun 2, 2006
Start date
Jun 2006
Primary completion
Oct 2007
Completion
Oct 2007
Last update
May 4, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion